Short answer
Inhibikase Therapeutics, Inc. (IKT) filed its Q3 2026 10-Q quarterly report on Nov 10, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$20M
- −71.6% YoY · −4.5% QoQ
- EPS (diluted)
- −$0.10
- +28.6% YoY · +9.1% QoQ
Source: XBRL data from the Inhibikase Therapeutics, Inc. (IKT) Q3 2026 10-Q on SEC EDGAR. USD.
Inhibikase Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $0, unchanged YoY, no commercial product sales
- Net loss $20.5M vs $11.9M YoY, operating loss $22.2M vs $12.8M
- PAH R&D $12.5M vs $5.6M, strongest program, Parkinson’s R&D $0 vs $0.3M
- Cash, equivalents and marketable securities $193.3M at September 30, 2026
- Nine-month operating cash use $41.9M vs $20.3M, financing provided $53.3M
- Outlook: funding expected through topline Phase 3 readout, additional capital likely needed due to ongoing losses
Risk Factors
- China-related regulation: BIOSECURE Act restrictions could force transition from WuXi AppTec subsidiary STA, delaying IKT-001 supply
- Most material update: WuXi AppTec added to Section 1260H list in June 2026, with designation challenged and preliminarily enjoined August 7, 2026
- Compliance risk: proposed restrictions on China-based clinical data could limit trial-site use and increase development costs
- Operational risk: third-party manufacturing deviations or scale-up failures could delay clinical trials and product launches
- Supply-chain concentration: STA Pharmaceutical Hong Kong manufactures and supplies IKT-001 drug substance and drug product
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Inhibikase Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.